Author:
Coen John J.,Rodgers Joseph P.,Saylor Philip J.,Lee Cheryl T.,Wu Chin-Lee,Parker William,Lautenschlaeger Tim,Zietman Anthony L.,Efstathiou Jason,Jani Ashesh B.,Kucuk Omer,Souhami Luis,Pugh Stephanie L.,Sandler Howard M.,Shipley William U.
Reference25 articles.
1. Treatment of nonmetastatic muscle-invasive bladder cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology clinical practice guideline summary;Chang;J Oncol Pract,2017
2. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines;Witjes;Eur Urol,2021
3. National Comprehensive Cancer Network. NCCN Guidelines – Bladder Cancer, Version 3.2023. 2023. Accessed August 28, 2023. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
4. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: An updated analysis of the Massachusetts General Hospital experience;Giacalone;Eur Urol,2017
5. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233;Mak;J Clin Oncol,2014